Mehilaeinen Oy

Helsinki 11 trials 6 recruiting

11 Registered trials

6 Currently recruiting

Organisation

Mehilaeinen Oy

Location

Helsinki, Finland

Identifier

ORG-100047145

Address

Saukonpaadenranta 2, 00180, Finland

Departments

6900: Neuro Neo Turku
Docrates Mehiläinen Cancer Center
Mehilaeinen FInlayson
Mehilaeinen Oy
NA
Satakunnan Psykiatripalvelu
Satakunnan psykiatripalvelu Oy
Silmäsairaala

Clinical trials at this site (11)

Search interface

Systemic nitrates in refractory normal tension glaucoma Pending

2025-522059-24-00 Normal tension glaucoma 6
Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519423-24-00 Major Depressive Disorder 5 2025-10-07
A study to learn how safe the study treatment actinium-225-macropa-pelgifatamab (BAY3546828) is, how it affects the body, how it moves into,… Recruiting

2022-502623-22-00 Metastatic castration-resistant prostate cancer 1 2023-09-18
A study to assess the efficacy and safety of ITI-1284 as adjunctive treatment in patients with Generalized Anxiety Disorder Recruiting

2024-513302-56-00 Generalized Anxiety Disorder 4 2025-11-17
Study to assess the efficacy and safety of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519421-37-00 Major Depressive Disorder 5 2025-08-28
A study to assess the efficacy and safety of ITI-1284 as monotherapy treatment in patients with Generalized Anxiety Disorder Recruiting

2024-516684-82-00 Generalized Anxiety Disorder 4 2025-07-21
First-in-human study of 225Ac-PSMA-Trillium (BAY 3563254) in participants with advanced metastatic castration-resistant prostate cancer (mCR… Recruiting

2023-507486-26-00 Advanced metastatic castration-resistant prostate cance 1 2024-08-20
A study to learn more about how well elinzanetant works and how safe it is compared to placebo for the treatment of hot flashes caused by an… Ended

2023-508265-33-00 Vasomotor symptoms caused by adjuvant endocrine therapy 5 2022-10-13
An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended

2023-507906-15-00 Relapsing multiple sclerosis (RMS) 5 2019-01-30
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as … Ended

2024-511557-21-00 Major Depressive Disorder (MDD) with Moderate-to-severe 5 2024-11-14
Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema)– Measure Up 1 Ended

2022-502938-30-00 Moderate and Severe Atopic Dermatitis 5 2018-12-10